A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a net loss of $131.01 million. Despite setbacks, advancements in clinical trials and partnerships with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results